1. Warren Buffett's investment in UnitedHealth reinforces the author's strong buy rating, highlighting long-term value despite recent challenges like earnings misses and higher medical costs. 2. UnitedHealth maintains robust revenue growth in key segments and offers a 2.76% dividend yield, supported by strong cash flows and a solid balance sheet. 3. The author recommends buying UNH on price weakness (below $300) for patient, long-term investors, emphasizing its appeal for dividend and value strategies.